Safety and efficacy of adalimumab in patients with rheumatoid arthritis not adequately responding to standard antirheumatic therapies

Trial Profile

Safety and efficacy of adalimumab in patients with rheumatoid arthritis not adequately responding to standard antirheumatic therapies

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms STAR
  • Most Recent Events

    • 17 Jun 2017 Results of post-hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top